Profil
Raymond Goodrich is the founder of PhotonPharma, Inc. and currently holds the title of CSO & Vice President-Research & Development at the company.
Aktive Positionen von Raymond Goodrich
| Unternehmen | Position | Beginn |
|---|---|---|
PhotonPharma, Inc.
 PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
PhotonPharma, Inc.
PhotonPharma, Inc. BiotechnologyHealth Technology PhotonPharma, Inc. is a company that is developing a personalized therapeutic cancer vaccine called Innocell. The company is based in Fort Collins, CO, at the Research Innovation Center of Colorado State University. The vaccine is designed using autologous tumor tissue and a photochemical inactivation platform that uses riboflavin and UV light to render tumor cells incapable of replication while still being able to metabolize, express proteins, present antigen, and stimulate immune recognition and response mechanisms. The company has demonstrated the ability of this technology to prevent metastatic tumor formation, reduce the growth of tumors, and stimulate cellular immune response pathways in preclinical development animal models. The company was founded in 2018 by Raymond Goodrich, and the CEO is Alan S. Rudolph. | Health Technology |